Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib

Over the last decades, a better understanding of breast cancer heterogeneity provided tools for a biologically based personalization of anticancer treatments. In particular, the overexpression of the human epidermal growth factor receptor 2 (HER2) by tumor cells provided a specific target in these H...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Kourie, Hampig Raphael, El Rassy, Elie, Clatot, Florian, de Azambuja, Evandro, Lambertini, Matteo
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2017
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5513878/
https://ncbi.nlm.nih.gov/pubmed/28744140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S122397
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky